A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia

This randomized phase 3 clinical trial evaluated the potential benefit of the addition of gemtuzumab ozogamicin (GO) to standard induction and postconsolidation therapy in patients with acute myeloid leukemia. Patients were randomly assigned to receive daunorubicin (45 mg/m(2) per day on days 1, 2,...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Petersdorf, Stephen H., Kopecky, Kenneth J., Slovak, Marilyn, Willman, Cheryl, Nevill, Thomas, Brandwein, Joseph, Larson, Richard A., Erba, Harry P., Stiff, Patrick J., Stuart, Robert K., Walter, Roland B., Tallman, Martin S., Stenke, Leif, Appelbaum, Frederick R.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2013
Témata:
Clinical Trials and Observations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3682338/
https://ncbi.nlm.nih.gov/pubmed/23591789
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-01-466706
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky